ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 07, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 3, 2022 (the “Grant Date”), ORIC granted a total of 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees who began their employment with ORIC in September 2022.